MA-LINEDATA
16.3.2021 08:32:07 CET | Business Wire | Press release
Linedata, a global provider of credit and asset management technology, data and services, today announced it is the first technology vendor to seamlessly integrate Environmental, Social, and Governance (ESG) data into asset managers’ workflows through collaboration with leading independent provider Arabesque S-Ray . A wide range of ESG data assets feeds directly into Linedata’s software to help managers meet growing demands from regulators and investors for greater transparency over ESG funds, and to provide a competitive edge through sustainable positioning and differentiated product offerings.
Arabesque S-Ray’s quantitative data tool uses machine learning to crunch the sustainability performance of over 8,000 of the world’s largest listed companies, and directly integrates with Linedata’s portfolio and order management solutions for unparalleled ease of use. It is available to Linedata clients in Europe, Asia, and North America.
“We believe economic value creation can go hand in hand with environmental stewardship, social inclusion, and sound governance,” noted Georg Kell, Chairman of the Arabesque Group, and founding Executive Director of the United Nations Global Compact. “Our agreement with Linedata empowers more asset managers to make better decisions for a sustainable future.”
Positioning powerful ESG intelligence at the fingertips of Linedata’s over 450 global asset management clients helps managers support ESG decision-making and adapt to evolving requirements under Europe’s new Sustainable Finance Disclosure Regulation (SFDR) and the United States’ new ESG agenda.
The move also marks an expansion of Linedata’s Data Management Service, a key component of its cloud-based Asset Management Platform - AMP launched last year. It offers an innovative commercial model which gives basic ESG and UN Global Compact scores to users of Linedata software, and the flexibility to access premium data on a usage basis, a break from the industry standard.
“Linedata is committed to helping market participants to make more and better ESG driven decisions. With sustainable fund assets hitting a record $1.7 trillion in 20201 , asset managers recognize ethical and sustainable funds as a major growth opportunity,” said Gary Brackenridge, Linedata’s Global Head of Asset Management. “The combination of Arabesque’s market-leading ESG data seamlessly integrated into Linedata’s cloud-based portfolio workflows with a unique usage model fits with what we know clients are looking for: commercial flexibility, high-value content and excellent user experience.”
Providing instant access to Arabesque S-Ray’s data supports the wider industry shift to ESG investing, while removing a major operational burden from asset managers. The ability to leverage independently validated ESG scores streamlines and accelerates the development of ethical, sustainable and funds and in turn helps guide which companies consciously minded investors and consumers choose to support.
Users benefit from ESG data insights throughout the entirety of their investment operations:
- Score, rebalance, and create new ESG portfolio strategies, products, and workflows
- Integrate ESG factors into pre- and post-trade Compliance at asset and fund level
- Manage regulatory and investor transparency and reporting with dashboards, screening, and monitoring tools
To learn more about Linedata’s Data Management Service - ESG Inside, visit linedata.com/ESG
Linedata is pleased to have won Best Data Management Solution at Hedgeweek European Awards 2021 at a virtual gala on Thursday March 11, 2021.
1 Sustainable investment indexes outperform and protect on the downside: Morningstar , 16.02.21
ABOUT ARABESQUE S-RAY
S-Ray® is an AI-based tool developed by Arabesque that analyses the sustainability performance of approximately 8,000 of the world’s largest listed corporations using self-learning quantitative models and data scores. The technology systematically combines over 200 ESG metrics with news signals from over 30,000 sources across 170 countries. It is the first tool of its kind to rate companies on the normative principles of the United Nations Global Compact (GC Score). Additionally, S-Ray provides an industry-specific assessment of companies’ performance on financially material sustainability criteria (ESG Score). Both scores are combined with a preferences filter that assesses a company’s business involvements. S-Ray daily data products and services are used by some of the world’s leading financial institutions, investors, corporations, and consultants.
ABOUT LINEDATA
With 20 years’ experience and 700 clients in 50 countries, Linedata’s 1100 employees in 20 offices provide global humanized technology solutions and services for the asset management and credit industries that help its clients to evolve and to operate at the highest levels.
Headquartered in France, Linedata achieved revenues of EUR 161.0 million in 2020 and is listed on Euronext Paris compartment B FR0004156297-LIN – Reuters LDSV.PA – Bloomberg LIN:FP.
linedata.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005350/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom